Copyright Reports & Markets. All rights reserved.

Global and Japan Castration Resistant Prostate Cancer Treatment Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Castration Resistant Prostate Cancer Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Hormonal Therapy
    • 1.2.3 Adding An Anti-Androgen
    • 1.2.4 Stopping An Anti-Androgen
    • 1.2.5 Estrogens
    • 1.2.6 Chemotherapy
    • 1.2.7 Radiation Therapy
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Castration Resistant Prostate Cancer Treatment Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Ambulatory Surgical Centers
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Castration Resistant Prostate Cancer Treatment Market Perspective (2015-2026)
  • 2.2 Global Castration Resistant Prostate Cancer Treatment Growth Trends by Regions
    • 2.2.1 Castration Resistant Prostate Cancer Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Castration Resistant Prostate Cancer Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Market Size
    • 3.1.1 Global Top Castration Resistant Prostate Cancer Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Castration Resistant Prostate Cancer Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Castration Resistant Prostate Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Castration Resistant Prostate Cancer Treatment Revenue
  • 3.4 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio
    • 3.4.1 Global Castration Resistant Prostate Cancer Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Castration Resistant Prostate Cancer Treatment Revenue in 2019
  • 3.5 Key Players Castration Resistant Prostate Cancer Treatment Area Served
  • 3.6 Key Players Castration Resistant Prostate Cancer Treatment Product Solution and Service
  • 3.7 Date of Enter into Castration Resistant Prostate Cancer Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Castration Resistant Prostate Cancer Treatment Breakdown Data by Type (2015-2026)

  • 4.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Type (2021-2026)

5 Castration Resistant Prostate Cancer Treatment Breakdown Data by Application (2015-2026)

  • 5.1 Global Castration Resistant Prostate Cancer Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Castration Resistant Prostate Cancer Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
  • 6.2 North America Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
  • 6.3 North America Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
  • 6.4 North America Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
  • 7.2 Europe Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
  • 8.2 China Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
  • 8.3 China Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
  • 8.4 China Castration Resistant Prostate Cancer Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
  • 9.2 Japan Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
  • 9.3 Japan Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
  • 9.4 Japan Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size (2015-2026)
  • 10.2 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Castration Resistant Prostate Cancer Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Active Biotech
    • 11.1.1 Active Biotech Company Details
    • 11.1.2 Active Biotech Business Overview
    • 11.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Introduction
    • 11.1.4 Active Biotech Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020))
    • 11.1.5 Active Biotech Recent Development
  • 11.2 Diagnocure
    • 11.2.1 Diagnocure Company Details
    • 11.2.2 Diagnocure Business Overview
    • 11.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Introduction
    • 11.2.4 Diagnocure Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.2.5 Diagnocure Recent Development
  • 11.3 Glaxosmithkline
    • 11.3.1 Glaxosmithkline Company Details
    • 11.3.2 Glaxosmithkline Business Overview
    • 11.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Introduction
    • 11.3.4 Glaxosmithkline Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.3.5 Glaxosmithkline Recent Development
  • 11.4 Northwest Biotherapeutics
    • 11.4.1 Northwest Biotherapeutics Company Details
    • 11.4.2 Northwest Biotherapeutics Business Overview
    • 11.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Introduction
    • 11.4.4 Northwest Biotherapeutics Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.4.5 Northwest Biotherapeutics Recent Development
  • 11.5 Millennium Pharmaceuticals
    • 11.5.1 Millennium Pharmaceuticals Company Details
    • 11.5.2 Millennium Pharmaceuticals Business Overview
    • 11.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
    • 11.5.4 Millennium Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.5.5 Millennium Pharmaceuticals Recent Development
  • 11.6 Hologic
    • 11.6.1 Hologic Company Details
    • 11.6.2 Hologic Business Overview
    • 11.6.3 Hologic Castration Resistant Prostate Cancer Treatment Introduction
    • 11.6.4 Hologic Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.6.5 Hologic Recent Development
  • 11.7 Spectrum Pharmaceuticals
    • 11.7.1 Spectrum Pharmaceuticals Company Details
    • 11.7.2 Spectrum Pharmaceuticals Business Overview
    • 11.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
    • 11.7.4 Spectrum Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.7.5 Spectrum Pharmaceuticals Recent Development
  • 11.8 Abbott Laboratories
    • 11.8.1 Abbott Laboratories Company Details
    • 11.8.2 Abbott Laboratories Business Overview
    • 11.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Introduction
    • 11.8.4 Abbott Laboratories Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.8.5 Abbott Laboratories Recent Development
  • 11.9 Bayer Healthcare Pharmaceuticals
    • 11.9.1 Bayer Healthcare Pharmaceuticals Company Details
    • 11.9.2 Bayer Healthcare Pharmaceuticals Business Overview
    • 11.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Introduction
    • 11.9.4 Bayer Healthcare Pharmaceuticals Revenue in Castration Resistant Prostate Cancer Treatment Business (2015-2020)
    • 11.9.5 Bayer Healthcare Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Castration Resistant Prostate Cancer Treatment Scope and Market Size
    Castration Resistant Prostate Cancer Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Castration Resistant Prostate Cancer Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Hormonal Therapy
    Adding An Anti-Androgen
    Stopping An Anti-Androgen
    Estrogens
    Chemotherapy
    Radiation Therapy
    Others

    Market segment by Application, split into
    Hospital
    Ambulatory Surgical Centers

    Based on regional and country-level analysis, the Castration Resistant Prostate Cancer Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Castration Resistant Prostate Cancer Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Active Biotech
    Diagnocure
    Glaxosmithkline
    Northwest Biotherapeutics
    Millennium Pharmaceuticals
    Hologic
    Spectrum Pharmaceuticals
    Abbott Laboratories
    Bayer Healthcare Pharmaceuticals

    Buy now